Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Marie-Cécile Nassogne is active.

Publication


Featured researches published by Marie-Cécile Nassogne.


Journal of Cognitive Neuroscience | 2010

Neural correlates of symbolic number comparison in developmental dyscalculia

Christophe Mussolin; Anne De Volder; Cécile Grandin; Xavier Schlögel; Marie-Cécile Nassogne; Marie-Pascale Noël

Developmental dyscalculia (DD) is a deficit in number processing and arithmetic that affects 3–6% of schoolchildren. The goal of the present study was to analyze cerebral bases of DD related to symbolic number processing. Children with DD aged 9–11 years and matched children with no learning disability history were investigated using fMRI. The two groups of children were controlled for general cognitive factors, such as working memory, reading abilities, or IQ. Brain activations were measured during a number comparison task on pairs of Arabic numerals and a color comparison task on pairs of nonnumerical symbols. In each task, pairs of stimuli that were close or far on the relevant dimension were constituted. Brain activation in bilateral intraparietal sulcus (IPS) was modulated by numerical distance in controls but not in children with DD. Moreover, although the right IPS responded to numerical distance only, the left IPS was influenced by both numerical and color distances in control children. Our findings suggest that dyscalculia is associated with impairment in areas involved in number magnitude processing and, to a lesser extent, in areas dedicated to domain-general magnitude processing.


Journal of Inherited Metabolic Disease | 2005

Urea cycle defects: management and outcome.

Marie-Cécile Nassogne; B. Héron; Guy Touati; D. Rabier; J. M. Saudubray

SummaryThis paper reviews the clinical presentation of 217 patients with urea cycle defects, including 121 patients with neonatal-onset forms and 96 patients with late-onset forms. Long-term outcome of these patients is also reported with the severity of the neonatal forms of these disorders, mostly for ornithine carbamoyltransferase-deficient males. Patients with late-onset forms may present at any age and carry a 28% mortality rate and a subsequent risk of subsequent disabilities.


Neuropediatrics | 2007

Folate Receptor Autoimmunity and Cerebral Folate Deficiency in Low-Functioning Autism with Neurological Deficits

Vincent Ramaekers; Nenad Blau; Jeffrey M. Sequeira; Marie-Cécile Nassogne; Edward V. Quadros

Reduced folate transport to the CNS was identified in two autism spectrum disorders, i.e., Rett syndrome and infantile low-functioning autism with neurological abnormalities. Twenty-five patients with early-onset low-functioning autism with or without neurological deficits, were evaluated for serum folate, cerebrospinal fluid (CSF) 5-methyltetrahydrofolate (5MTHF), and serum FR autoantibodies of the blocking type to determine the significance of folate receptor (FR) autoantibodies with respect to folate transport across the blood-CSF barrier. In spite of normal serum folate, CSF 5MTHF was low in 23 of 25 patients. The reduced CSF folate in 19 of these 23 patients could be explained by serum FR autoantibodies blocking the folate binding site of the membrane-attached FR on the choroid epithelial cells. Oral folinic acid supplements led to normal CSF 5MTHF and partial or complete clinical recovery after 12 months. Serum FR autoimmunity appears to represent an important factor in the pathogenesis of reduced folate transport to the nervous system among children with early-onset low-functioning autism associated with or without neurological deficits. Early detection of FR autoantibodies may be a key factor in the prevention and therapeutic intervention among this subgroup of patients with autism.


Mammalian Genome | 1995

Disruption of Murine Hexa Gene Leads To Enzymatic Deficiency and To Neuronal Lysosomal Storage, Similar To That Observed in Tay-sachs-disease

Michel Cohen-Tannoudji; P. Marchand; S. Akli; Sa. Sheardown; Jp. Puech; Chantal Kress; Pierre Gressens; Marie-Cécile Nassogne; T. Beccari; Al. Muggletonharris; Patrick Evrard; Jl. Stirling; L. Poenaru; Charles Babinet

Tay-Sachs disease is an autosomal recessive lysosomal storage disease caused by β-hexosaminidase A deficiency and leads to death in early childhood. The disease results from mutations in the HEXA gene, which codes for the α chain of β-hexosaminidase. The catastrophic neurodegenerative progression of the disease is thought to be a consequence of massive neuronal accumulation of GM2 ganglioside and related glycolipids in the brain and nervous system of the patients. Fuller understanding of the pathogenesis and the development of therapeutic procedures have both suffered from the lack of an animal model. We have used gene targeting in embryonic stem (ES) cells to disrupt the mouse Hexa gene. Mice homozygous for the disrupted allele mimic several biochemical and histological features of human Tay-Sachs disease. Hexa-/-mice displayed a total deficiency of β-hexosaminidase A activity, and membranous cytoplasmic inclusions typical of GM2 gangliosidoses were found in the cytoplasm of their neurons. However, while the number of storage neurons increased with age, it remained low compared with that found in human, and no apparent motor or behavioral disorders could be observed. This suggests that the presence of β-hexosaminidase A is not an absolute requirement of ganglioside degradation in mice. These mice should help us to understand several aspects of the disease as well as the physiological functions of hexosaminidase in mice. They should also provide a valuable animal model in which to test new forms of therapy, and in particular gene delivery into the central nervous system.


Journal of Medical Genetics | 2013

Phenotype and genotype in 101 males with X-linked creatine transporter deficiency

J.M. van de Kamp; Ofir T. Betsalel; Saadet Mercimek-Mahmutoglu; L Abulhoul; S Grünewald; Irina Anselm; H Azzouz; Drago Bratkovic; A.P.M. de Brouwer; B.C.J. Hamel; Tjitske Kleefstra; Helger G. Yntema; Jaume Campistol; M. A. Vilaseca; D. Cheillan; M D'Hooghe; Luísa Diogo; Paula Garcia; Carla Valongo; M Fonseca; Suzanna G M Frints; Bridget Wilcken; S von der Haar; Hanne Meijers-Heijboer; F Hofstede; D Johnson; Sarina G. Kant; L. Lion-François; Gaëlle Pitelet; Nicola Longo

Background Creatine transporter deficiency is a monogenic cause of X-linked intellectual disability. Since its first description in 2001 several case reports have been published but an overview of phenotype, genotype and phenotype–genotype correlation has been lacking. Methods We performed a retrospective study of clinical, biochemical and molecular genetic data of 101 males with X-linked creatine transporter deficiency from 85 families with a pathogenic mutation in the creatine transporter gene (SLC6A8). Results and conclusions Most patients developed moderate to severe intellectual disability; mild intellectual disability was rare in adult patients. Speech language development was especially delayed but almost a third of the patients were able to speak in sentences. Besides behavioural problems and seizures, mild to moderate motor dysfunction, including extrapyramidal movement abnormalities, and gastrointestinal problems were frequent clinical features. Urinary creatine to creatinine ratio proved to be a reliable screening method besides MR spectroscopy, molecular genetic testing and creatine uptake studies, allowing definition of diagnostic guidelines. A third of patients had a de novo mutation in the SLC6A8 gene. Mothers with an affected son with a de novo mutation should be counselled about a recurrence risk in further pregnancies due to the possibility of low level somatic or germline mosaicism. Missense mutations with residual activity might be associated with a milder phenotype and large deletions extending beyond the 3′ end of the SLC6A8 gene with a more severe phenotype. Evaluation of the biochemical phenotype revealed unexpected high creatine levels in cerebrospinal fluid suggesting that the brain is able to synthesise creatine and that the cerebral creatine deficiency is caused by a defect in the reuptake of creatine within the neurones.


Pediatrics | 2005

Long-term Follow-up of Neonatal Mitochondrial Cytopathies: A Study of 57 Patients

Angels García-Cazorla; P. De Lonlay; Marie-Cécile Nassogne; P. Rustin; Guy Touati; J. M. Saudubray

Objectives. We sought to determine the long-term clinical and biochemical outcome of newborns with mitochondrial cytopathies (MCs) and to identify possible prognostic factors that may modify the course of these diseases. Material and Methods. Fifty-seven newborns with MCs were identified in a retrospective review (1983–2002). We defined 2 different outcome categories: clinical (neurologic, hepatic, myopathic, and multiorganic) and biochemical (lactate level normalization or initially normal remaining unchanged, decreased but not normalized, and persistently high). We used 2 different statistical approaches: (1) survival studies depending on the initial symptoms and lactate and enzymatic deficiencies using the Kaplan-Meier method; and (2) the same variables compared with different survival age groups and clinical and biochemical outcome categories using the χ2 test. Results. Thirty-three patients died (57.8%), 12 remain alive (21%), and 12 were lost in the follow-up; 6 of them are currently older than 4 years. Most of the patients manifested multiorganic disease (64.8%) and high lactate level (77.1%) over time. Children surviving to 2.5 to 3 years of age were more likely to survive for a long period of time. Initial neurologic and hepatic presentation increased the risk to develop neurologic disease and severe persistent hyperlactacidemia, respectively. Initial severe hyperlactacidemia and combined enzyme deficiencies were significant risk factors for higher mortality and multiorganic disorders. Two patients with exclusively myopathic outcome are alive and cognitively normal at 12 years of life. Conclusions. Children with neonatal-onset MCs have very high mortality and poor prospects. However, some with life-threatening presentations may gradually improve, giving rise to less severe diseases. Those with exclusively myopathic symptoms have a better prognosis.


American Journal of Medical Genetics | 1999

Albinism and agenesis of the corpus callosum with profound developmental delay : Vici syndrome, evidence for autosomal recessive inheritance

Miguel del Campo; Bryan D. Hall; Alec Aeby; Marie-Cécile Nassogne; Alain Verloes; Carmen Roche; Carmen González; Honorio Sanchez; Alfredo Garcia-Alix; Fernando Cabañas; Rosa M. Escudero; Rafael Mas Hernández; José Quero

We report on two sibs and two other unrelated patients with agenesis of corpus callosum, oculocutaneous albinism, repeated infections, and cardiomyopathy. All manifested postnatal growth retardation, microcephaly, and profound developmental delay. Additional central nervous system anomalies present in at least one patient included hypoplasia of the cerebellar vermis, white matter neuronal heterotopia, or bilateral schizencephaly. Repeated viral, bacterial, and fungal infections were consistent with a primary immunodeficiency. However, immunological studies showed variable, nonspecific findings. Cardiomyopathy with progressive heart failure or infection led to death before age 2 years in three of the patients. This syndrome was first described by Vici et al. [1988: Am. J. Med. Genet. 29:1-8]. The four patients reported herein confirm this unique disorder. Affected sibs of both sexes born to unaffected parents provide evidence for autosomal recessive inheritance.


European Journal of Human Genetics | 2002

Overgrowth and trisomy 15q26.1-qter including the IGF1 receptor gene: report of two families and review of the literature

L. Faivre; Philippe Gosset; Valérie Cormier-Daire; Sylvie Odent; Jeanne Amiel; Irina Giurgea; Marie-Cécile Nassogne; Laurent Pasquier; Arnold Munnich; Serge Romana; Marguerite Prieur; Michel Vekemans; Marie-Christine de Blois; Catherine Turleau

Overgrowth is rarely associated with chromosomal imbalances. Here we report on four children from two unrelated families presenting with overgrowth and a terminal duplication of the long arm of chromosome 15 diagnosed using cytogenetic and FISH studies. In both cases, chromosome analysis of the parents showed a balanced translocation involving 15q26.1-qter. Molecular and cytogenetic studies showed three copies of the insulin-like growth factor 1 receptor (IGF1R) gene. This finding suggests that overgrowth observed in our patients might be causally related to a dosage effect of the IGF1R gene, in contrast to severe growth retardation observed in patients with terminal deletion of 15q. The present observation emphasises the importance of chromosome analysis in patients with overgrowth and mental retardation. Moreover, it further delineates a specific phenotype related to trisomy 15q26.1-qter with macrosomia at birth, overgrowth, macrocephaly and mild developmental delay being the major clinical features.


Seizure-european Journal of Epilepsy | 2010

Treatment and long term outcome in West syndrome: the clinical reality. A multicentre follow up study.

Lieven Lagae; Helene Verhelst; Berten Ceulemans; Linda De Meirleir; Marie-Cécile Nassogne; Valerie De Borchgrave; Marc D’Hooghe; Martine Foulon; Patrick Van Bogaert

We systematically reviewed the files of 51 infants presenting with infantile spasms and hypsarrhythmia in order to study the initial treatment strategies and the long term outcome. 80% of the infants were classified as symptomatic. In the nine participating centres, different treatment protocols were used, but the large majority of the children received vigabatrin as first line treatment. Second line options included hormonal treatment, topiramate and valproate. The time to reach cessation of infantile spasms was significantly shorter in the cryptogenic group than in the symptomatic group (50% at 13 days versus 66 days respectively) and was irrespective of the treatment used. The late follow up data (>2 years) showed that 60% of the children had epilepsy and that 75% of the children had a delay in their psychomotor development. Again, outcome in the cryptogenic group was better than in the symptomatic group, but also in the cryptogenic group, 50% of the children had a clear developmental delay, even if spasms were controlled early in the course of the disease. Our retrospective study illustrates that not only the underlying brain dysfunction is the major determinant for later outcome in infantile spasms (symptomatic group) but also even a short period of infantile spasms can be responsible for later developmental delay (cryptogenic group).


Pediatric Radiology | 2001

Pancreatic arterial calcium stimulation in the diagnosis and localisation of persistent hyperinsulinemic hypoglycaemia of infancy

Valerie Chigot; Pascale de Lonlay; Marie-Cécile Nassogne; Kathleen Laborde; Véronique Delagne; Jean-Christophe Fournet; Claire Nihoul-Fékété; Jean-Marie Saudubray; Francis Brunelle

Abstract.Background: Persistent hyperinsulinemic hypoglycaemia of infancy (PHHI) is often resistant to medical therapy. Surgery is therefore necessary. It is due to focal adenomatous islet-cell hyperplasia treatable by partial pancreatectomy, or diffuse beta-cell hyperfunction, which requires near-total pancreatectomy. Pancreatic venous sampling (PVS) is the reference technique for the preoperative diagnosis and localization of focal forms of PHHI in the pancreas. However, hypoglycaemia is necessary to analyse the results and PVS is technically challenging. Pancreatic arterial calcium stimulation (PACS) is technically easier and does not require hypoglycaemia. Aim: To study the accuracy in the diagnosis and localization of PHHI. Materials and methods: PACS was performed in 12 patients and correlated with histology. Results: The accuracy of PACS is poor in diffuse lesions since only two of six cases were correctly identified by this test. Five of six focal lesions were correctly recognized and located. Conclusions: PACS is less accurate than PVS in PHHI. Currently, it should be performed only when PVS fails.

Collaboration


Dive into the Marie-Cécile Nassogne's collaboration.

Top Co-Authors

Avatar

Marie-Françoise Vincent

Université catholique de Louvain

View shared research outputs
Top Co-Authors

Avatar

Philippe Kinoo

Cliniques Universitaires Saint-Luc

View shared research outputs
Top Co-Authors

Avatar

Isabelle Roskam

Université catholique de Louvain

View shared research outputs
Top Co-Authors

Avatar

Christine Saint-Martin

Cliniques Universitaires Saint-Luc

View shared research outputs
Top Co-Authors

Avatar

Yves Sznajer

Université catholique de Louvain

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Philippe Clapuyt

Cliniques Universitaires Saint-Luc

View shared research outputs
Top Co-Authors

Avatar

Christine Bonnier

Cliniques Universitaires Saint-Luc

View shared research outputs
Top Co-Authors

Avatar

Etienne Sokal

Université catholique de Louvain

View shared research outputs
Top Co-Authors

Avatar

Hazim Kadhim

Université libre de Bruxelles

View shared research outputs
Researchain Logo
Decentralizing Knowledge